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Abstract Background and Objective: Dextromethorphan/quinidine (DMQ) is the first
agent indicated for the treatment of pseudobulbar affect. Dextromethorphan,
the active ingredient, is a low-affinity, uncompetitive N-methyl-D-aspartate
(NMDA) receptor antagonist. This study evaluated the potential for a drug-
drug interaction (DDI) of DMQ with memantine, which is also an NMDA
receptor antagonist.
Methods: This open-label, randomized, parallel-group study enrolled healthy
adults who were randomized into one of two treatment groups. Group 1
subjects were administered memantine at a starting dose of 5mg once daily,
which was titrated over a 3-week period to a dose of 10mg twice daily (every
12 hours) and continued for another 11 days to attain steady state; DMQ
30mg (dextromethorphan 30mg/quinidine 30mg) every 12 hours was then
added for a further 8 days. Group 2 subjects receivedDMQ30mg every 12 hours
for 8 days to attain steady state; memantine was then added, titrated on the
same schedule as in group 1, and continued at 10mg every 12 hours for an
additional 11 days. Pharmacokinetic blood sampling was performed to assess
the primary endpoints of the 90% confidence intervals (CIs) for the geometric
mean ratios of the areas under the plasma concentration-time curves (AUCs)
for memantine, dextromethorphan, dextrorphan – the dextromethorphan
metabolite – and quinidine during concomitant therapy versus monotherapy.
Safety/tolerability and pharmacodynamic variables were also assessed.
Results: A total of 52 subjects were randomized. In both group 1 (n = 23) and
group 2 (n= 29), the 90% CIs for the ratios of the AUCs during concomitant
therapy versus monotherapy were within the predefined range to indicate
similarity (0.8–1.25) for memantine, dextromethorphan and dextrorphan,
indicating no pharmacokinetic DDI. The 90% CI for the AUC ratio for
ORIGINAL RESEARCH ARTICLE Clin Drug Investig 2012; 32 (8): e1-e151173-2563/12/0008-0001
Adisª 2012 Pope et al., publisher and licensee Springer International Publishing AG. This is an open access article published
under the terms of the Creative Commons License ‘‘Attribution-NonCommercial-NoDerivative 3.0’’
(http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits non-commercial use, distribution,
and reproduction, provided the original work is properly cited and not altered.
quinidine was slightly above the predefined range; however, the mean AUC
increased by only 25%. In both groups, incidence of adverse events was
similar, and pharmacodynamic variables were either similar or slightly im-
proved with DMQ added to memantine and memantine added to DMQ,
compared to monotherapy with either agent.
Conclusion: Minimal pharmacokinetic and pharmacodynamic interactions
were observed between memantine and DMQ, suggesting they can be coadmin-
istered without dose adjustment.
Background
Pseudobulbar affect (PBA) is a neurological
disorder of emotional affect, characterized by in-
voluntary, sudden and uncontrollable outbursts
of laughing and/or crying, which are often ex-
aggerated or incongruous to the stimulus or so-
cial context.[1-3] This syndrome occurs secondary
to neurological disease or brain injury, including
Alzheimer’s disease or dementia, multiple sclerosis,
Parkinson’s disease, amyotrophic lateral sclerosis,
stroke and traumatic brain injury, among other
conditions.[2] PBA episodes often cause severe
embarrassment and social dysfunction, and can
lead to social isolation, reduced quality of life and
impaired function for patients, independent of the
burdens of the underlying, primary disorder.[1,2,4-9]
Dextromethorphan/quinidine (DMQ) [Nue-
dexta, Avanir Pharmaceuticals, Inc., Aliso Viejo,
CA, USA; 2010] is the first agent indicated for
the treatment of PBA, based on evidence of its
safety and efficacy in randomized, controlled clinical
trials.[10-12] The US FDA-approved dosage of
DMQ is dextromethorphan 20mg and quinidine
10mg taken every 12 hours.[13] Dextromethor-
phan, the pharmacologically active ingredient of
DMQ, is a low-affinity, uncompetitiveN-methyl-
D-aspartate (NMDA) receptor antagonist,[14] a
serotonin reuptake inhibitor[15] and a sigma-1
receptor agonist.[16] Dextromethorphan is metabo-
lized by the polymorphic cytochrome P450 (CYP)
2D6, and undergoes rapid hepatic conversion to
its metabolite dextrorphan, such that plasma
concentrations of dextromethorphan are too low
in most patients to achieve therapeutic effect, even
at high doses.[17-19] For this reason, dextrometh-
orphan is combined with quinidine, a CYP2D6
inhibitor, which has been shown to increase the sys-
temic availability of dextromethorphan by blocking
its first-pass hepatic metabolism.[19] Dextromethor-
phan levels when coadministered with quinidine
(dextromethorphan 30mg+quinidine 30mg) after
repeated dosing have been reported to be 30- to
40-fold higher than levels of dextromethorphan
administered alone.[17]
Because patients with PBA have underlying
neurological conditions that may be treated with
a range of medications, and DMQ is a relatively
new agent to treat PBA, it is important to evaluate
the potential for drug-drug interactions. Mem-
antine is a voltage-dependent, moderate-affinity,
uncompetitive NMDA receptor antagonist, which
is indicated for the treatment of patients with
moderate to severe Alzheimer’s disease.[20] Al-
though there are limited data available on the
prevalence of PBA in this population, it has
been estimated that up to 39% of patients with
Alzheimer’s disease also experience PBA.[2,21]
Therefore, physicians may consider treating pa-
tients with Alzheimer’s disease with memantine
and DMQ concomitantly. Since both agents are
NMDA receptor antagonists, however, their co-
administration could, theoretically, lead to an
additive effect at NMDA receptors and increased
rates or severity of adverse events (AEs).[20]
In addition, quinidine may theoretically inhibit
memantine clearance, since both agents undergo
renal tubular transport and urinary excretion.[22-24]
Therefore, a study was conducted to assess the
pharmacokinetic and pharmacodynamic drug-
drug interactions resulting from coadministra-
tion of DMQ and memantine, and the safety and
tolerability of this combination. Of note, the dosage
of DMQ used in this study was dextromethor-
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phan 30mg/quinidine 30mg every 12 hours since
it was the DMQ dosage being investigated at the
time of the study, but is higher than the dosage




This was an open-label, randomized, parallel-
group clinical study in healthy adult subjects,
conducted at a single site, INCResearch – Toronto
(Ventana Clinical Research Corporation, Toronto,
Canada, at the time of the study). The study was
composed of a screening visit and a treatment period,
and subjects were randomized to two treatment
groups.
In group 1, subjects were administered mem-
antine at a starting dose of 5mg once daily, which
was titrated over a 3-week period to a dose of 10mg
twice daily (every 12 hours) [figure 1]. Upon
reaching the memantine 10mg every 12 hours
dose (day 22), group 1 subjects continued this
treatment for 11 days to attain steady-state drug
plasma levels, based on reported clinical data.[25]
DMQ 30mg (dextromethorphan 30mg/quinidine
30mg) every 12 hours was then added (starting
day 33) to the ongoing memantine treatment for
the next 8 days. In group 2, subjects received
DMQ 30mg every 12 hours for 8 days to attain
steady state (figure 1), and memantine was then
added (starting day 9) to the ongoing DMQ
therapy, with memantine administered at a start-
ing dose of 5mg once daily and titrated up to
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Fig. 1. Study design. In group 1 (top), subjects underwent 3-week titration of memantine to the target dose of 10mg every 12 hours, followed
by continuation of memantine 10mg every 12 hours for 11 days to achieve steady state, and then the addition of DMQ 30mg every 12 hours for
another 8 days. In group 2 (bottom), subjects took DMQ 30mg every 12 hours for 8 days to achieve steady state. Memantine was then added to
DMQ 30mg on the same titration schedule as in group 1 until the target dose (memantine 10mg every 12 hours) was reached, and then the
concomitant therapy was continued for another 11 days. On the final day of monotherapy and of concomitant therapy, blood sampling was
performed in each group for steady-state pharmacokinetic analysis (vertical arrows). DMQ =dextromethorphan 30mg/quinidine 30mg.
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memantine dose was reached (day 30), the DMQ
and memantine regimens were continued for an
additional 11 days. Pre-dose plasma samples
were obtained at several time points for both
memantine and DMQ to confirm whether steady-
state drug levels had been attained by the desig-
nated time point (day 11 for memantine, day 8
for DMQ).
This study was conducted in accordance with
the ethical principles stated in the Declaration of
Helsinki, 1964, amended in Edinburgh in 2000,
and Good Clinical Practice. Prior to initiation of
the study, the protocol, consent form, amend-
ments to the protocol and advertisements for
subject recruitment were reviewed and approved
by the Institutional Review Board of the partici-
pating study centre. Before participating in this
study, all subjects were required to sign informed,
written consent forms that encompassed all pro-
cedures and assessments to be performed during
the study, including genotyping.
Study Objectives
The primary objectives of this study were to
assess in healthy adults: the effect of DMQ on the
steady-state pharmacokinetics of memantine; the
effect of memantine on the steady-state pharmaco-
kinetics of DMQ; and the safety and tolerability
of coadministration of DMQ and memantine.
The secondary objectives of this study were to as-
sess the effects of the addition of DMQ on selected
pharmacodynamic measures associated with mem-
antine, and the effect of the addition of memantine




Eligible subjects were healthy men and women
aged 19–55 years of age (inclusive) who were non-
smokers (for at least 3 months prior to the screen-
ing visit); had a body weight of at least 60 kg for
men and at least 52 kg for women, and a body
mass index (BMI) of 19–30 kg/m2, inclusive; were
free from any clinically significant abnormality of
medical history; were able to abstain from alco-
hol (ethanol) from at least 2 weeks prior to the
start of the treatment period and until final dis-
charge, and had negative breath alcohol tests at
screening, and at each outpatient visit to the clinical
research unit. Women of reproductive potential
who were not abstinent from sex with men were
entered into the study if they were using and
would continue to use adequate contraception,
and had a negative serum pregnancy test at the
screening visit and throughout the study.
Exclusion Criteria
Subjects were excluded if they had a history or
present condition ofmajor organ or systemic disease
or psychiatric illness; substance abuse or depen-
dence; renal impairment (creatinine clearance
£50mL/min); myasthenia gravis, conjunctivitis
or urinary tract infections; severe gastrointestinal
narrowing or hepatic or renal impairment that
could interfere with drug absorption, distribution,
metabolism or elimination; a PR interval ‡190msec
at the screening visit or ‡200 msec prior to the
first dose of study medication; corrected QT
(QTc) prolongation (were taking medications or
had a condition known to prolong QTc, or whose
QTc interval was >450msec for men or >470msec
for women at the screening visit); had used any
drugs or substances known to be strong inhibi-
tors or inducers of CYP enzymes within 30 days
of the first study dose; had used any prescription
(except oral contraceptives or sex hormone re-
placement therapy) or non-prescription drugs or
natural health products (except vitamins/minerals
and paracetamol [acetaminophen] up to 2 g/day)
within 14 days of the first dose and for the dura-
tion of the study; use of monoamine oxidase inhi-
bitors, thioridazine, pimozide, serotonin-precursors
and other serotonergic drugs, antipsychotics, bar-
biturates, anti-epileptics, dantrolene or baclofen
within 21 days of the first study dose.
Other Restrictions and Prohibitions
Subjects were required to fast for approxi-
mately 8 hours prior to dosing on days requiring
post-dose pharmacokinetic sampling, and 2 hours
prior to dosing to 1 hour post dosing on all other
study days. Water was not permitted from 2 hours
pre-dose until 1 hour post-dose, except for the
125mL of non-carbonated water that was taken
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during each study drug administration. At all
other times water was permitted ad libitum. Sub-
jects also agreed to abstain for at least 2 weeks
prior to the first dose administration until final
discharge from foods and/or beverages that could
interfere with laboratory values or drug metabo-
lism. Strenuous exercise (defined as any activity
that resulted in a heart rate that was 70% or more
of the maximum resting heart rate) was not per-
mitted 48 hours prior to admission (treatment




The primary pharmacokinetic outcome vari-
ables of this study were the 90% confidence in-
tervals (CIs) of the true geometric mean ratios
for:
 Memantine area under the plasma concentra-
tion-time curve from 0 to 12 hours (AUC12) on
day 40 (memantine with DMQ) and day 32
(memantine alone);
 DMQ (dextromethorphan, dextrorphan and
quinidine) AUC12 on day 40 (DMQ with
memantine) and day 8 (DMQ alone).
Maximum steady-state concentration (Cmax,ss)
and minimum steady-state concentration (Cmin,ss),
time to reach maximum concentration (tmax) and
the apparent elimination half-life (t½) were also
examined for memantine and DMQ. To control
for genotype status, genotyping analysis ofCYP2D6
was conducted for each subject.
Blood Samples Collection and Analysis
Blood samples were collected at designated
times via an optional indwelling catheter or by
direct venipuncture for assessment of drug levels.
Blood samples for pharmacokinetic assessments
were obtained for the morning dose at 1 hour pre-
dose and 1, 2, 3, 4, 5, 6, 8 and 12 hours post-dose
for DMQ, and at 1 hour pre-dose and 2, 4, 6, 8, 10
and 12 hours post-dose for memantine. In group
1 pharmacokinetic assessments were conducted
for memantine on day 32, and for memantine and
DMQ on day 40; in group 2, pharmacokinetic
assessments were conducted for DMQ on day 8,
and for DMQ and memantine on day 40. Ad-
ditionally, to monitor progression to steady state,
blood sampling was performed within 5 minutes
prior to the first morning dose administration on
the following days: group 1 days 2, 5, 8, 11, 14, 17,
20, 23, 26 and 29–31 to assess memantine levels
and days 37–39 to assess DMQ levels, and group
2 days 2, 5–7, 10, 13, 16, 19, 22, 25 and 28 to
assess DMQ levels and days 10, 13, 16, 19, 22, 25,
28 and 37–39 to assess memantine levels.
In order to conduct dextromethorphan, dex-
trorphan and quinidine assays, a 6mL blood
sample was collected in a heparinized tube; for
memantine assays, a 5mL blood sample was
collected in an ethylenediaminetetraacetic acid-
containing tube. All blood samples were cooled in
an ice bath prior to processing and separated by
centrifugation at approximately 2500 rpm for
15 minutes at 4C. Following centrifugation, two
plasma aliquots per sample were placed in clearly
labelled polypropylene containers and stored in a
freezer at -20C or below until removed for
shipping; sample aliquots were shipped on dry ice
in two separate shipments, with the second set of
aliquots shipped after notification of receipt of
the first. Approximately 202mL of blood were
collected during the course of the study for
pharmacokinetic sampling in group 1 (26 blood
draws for memantine [130mL] and 12 blood
draws for DMQ [72mL]) and 259mL in group 2
(17 blood draws for memantine [85mL] and 29
blood draws for DMQ [174mL]).
MDS Pharma Services, Lincoln, NE, USA,
and Sittingbourne, UK, performed all analyses
of the plasma samples. The three bioanalytical
methods used for these analyses were all conducted
under Principles of Good Laboratory Practice des-
cribed in the Code of Federal Regulations title
21, part 58 and the Guidance for Industry –
Bioanalytical Method Validation (Center for
Drug Evaluation and Research, May 2001). The
plasma samples for dextromethorphan and dex-
trorphan were analysed by using a liquid chroma-
tography-tandemmass spectrometry (LC-MS/MS)
assay. In this assay, internal standards (d3-dextro-
methorphan hydrochloride and d3-dextrorphan
hydrobromide) were spiked into the plasma, and
the mixture was treated for enzymatic hydrolysis
and then extracted into an organic solvent. The
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organic phase was transferred to a clean tube,
evaporated to dryness and reconstituted for in-
jection on an LC-MS/MS (Applied Biosystems/
MDS Sciex API 4000). For dextromethorphan,
the linearity range was 0.2ng/mL to 200ng/mL
with a lower limit of quantitation (LLQ) of
0.2ng/mL; for dextrorphan these parameters were
2.5ng/mL to 2500ng/mLwith a LLQof 2.5ng/mL.
Quinidine was assayed using a validated high-
performance liquid chromatography (HPLC)
assay. Quinidine and the internal standard (qui-
nine) were isolated from plasma by protein pre-
cipitation with acetonitrile. Samples were diluted
with water before injection onto the HPLC. The
linearity range was 2–250 ng/mL, and the LLQ
was 2 ng/mL. Memantine was assayed using a
validated LC-MS/MS assay. An aliquot of the
study plasma sample containing added internal
standard (l-amantylamine hydrochloride) was
prepared using a solid-phase extraction proce-
dure. The extracted samples were analysed using
an HPLC equipped with a MDS Sciex API 4000
mass spectrometer. Quantification was by peak
area ratio. The linearity range was 0.1–30 ng/mL,
and the LLQ was 0.1 ng/mL.
For all assays, a single set of calibration stan-
dards placed near the beginning of each batch
defined a standard curve from which six replicates
of quality control samples at three concentrations
were determined. There were no significant in-
terfering peaks. Selectivity was demonstrated
against possible contaminants and metabolites.
Interday and intraday variability fell below 15%
(coefficient of variation and relative error).
For CYP2D6 genotyping analysis, a 10mL
whole blood sample was collected from each sub-
ject at any time on day -1 of the first treatment
period. Each sample was collected into a lavender
top polypropylene EDTA Vacutainer or equi-
valent and gently inverted ten times to ensure
proper mixing of the anticoagulant with the
blood sample. Samples were processed by Gen-
aissance, Morrisville, NC, USA for CYP2D6 *3,
*4, *5, *6, *7 and *8 alleles by multiplex poly-
merase chain reaction.[26] The analyses of the
CYP2D6 *5, *2XN, *10 and *17 alleles were each
done in separate assays. Based on the results,
predicted metabolizer phenotypes of extensive
metabolizer (EM), poor metabolizer (PM), inter-
mediate metabolizer (IM) or ultra-rapid metabo-
lizer (UM) were assigned for each sample. Each
sample was to be stored at Genaissance for no
longer than 2 years and then destroyed, having
been used only to determine CYP2D6 genotype
status.
Safety and Tolerability Variables
Safety and tolerabilitymeasures included physical
examination, vital signs, 12-lead electrocardiogram
(ECG), laboratory tests and monitoring of AEs,
including serious AEs (SAEs). Urine drug screens
were conducted at baseline and after the last
evening drug administration on days 8, 15, 22 and
31 in group 1, and on days 7, 9, 16, 23 and 28
in group 2. AEs were reported and recorded
throughout the study from the time informed
consent was obtained until discharge from the
study, including at follow-up (for SAEs following
the last dose of study drug), and were coded using
the Medical Dictionary for Regulatory Activities
(MedDRA).
Pharmacodynamic Variables
The secondary study outcomes were pharma-
codynamic measures selected based on the side-
effect profiles of the two drugs and included the
following: (1) The Choice Reaction Time (CRT),
a test of psychomotor function measuring speed
and accuracy with which subjects use a keypad to
input sequences of numbers that are displayed on
a corresponding computer screen image; the test
measures Recognition Reaction Time (RRT),
Motor Reaction Time (MRT) and Total Reac-
tion Time (RRT+MRT).[27] (2) The Divided At-
tention Test (DAT), a manual tracking and visual
target detection task comprised of an image of an
airplane and a randomly curving road. Subjects
are asked to use a joystick to keep the airplane
over the road while simultaneously responding to
random visual targets.[28] (3) The Postural Stabi-
lity Test, which uses a platform tomeasure variables
pertaining to body sway and postural stability.
Subjects are asked to stand on the platform for
over 1 minute with their eyes open and then with
their eyes closed. Summary variables are the area
of a 95% confidence ellipse (to track time-related
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sway in balance), the length of the path of the
centre-of-pressure coordinates and the total test
time completed.[29] (4) Visual analogue scales
(VAS) for nausea and dizziness consisting of
a horizontal line ranging from 0 to 100 with de-
scriptive anchor endpoints of ‘not at all’ and
‘extremely’. Subjects were asked to indicate on
the scale their responses to the statements ‘‘I feel
dizzy’’, and ‘‘I feel nauseous’’. (5) The Beck Depres-
sion Inventory, 2nd Edition (BDI-II), a 21-item
self-report scale measuring presence and degree
of depressive symptoms over the past 2 weeks.
Responses to each item correspond to a scale
from 0 (neutral) to 3 (maximum severity), with a
total possible score of 63.[30] (6) The Beck Anxiety
Inventory (BAI), a 21-item self-report scale mea-
suring common symptoms of anxiety. The sub-
ject rates each item (ranging from 0 to 3) based on
how much he/she has been bothered by each
symptom over the past week (total score 0–63).[31]
(7) The Leeds Sleep Evaluation Questionnaire
(LSEQ),[32] a 10-item self-rating scale measuring
perceived changes in sleep, ease of wakening and
alertness.
The pharmacodynamic measures were assessed
during peak drug levels (after the last morning
dose) on days 1, 8, 15, 22, 32, 33, 36 and 40 in
group 1 and on days 1, 8, 9, 15, 22, 29, 36 and 40
in group 2. The CRT, DAT, Postural Stability
and VAS scales were assessed at 2, 4 and 6 hours;
the LSEQ at 2 hours; and the BAI and BDI-II at
4 hours after dosing. A training session was con-
ducted on day -1 in both groups, and all subjects
underwent a pharmacodynamic refresher session
before dosing on the morning on which pharma-
codynamic measures were collected.
Statistical Methods
The sample size was planned to include 40
healthy volunteers (20 per treatment group) with
the intention of approximately 12 subjects com-
pleting in each treatment group. For a test of
equivalence, a sample size of 12 would have had a
power of 80%, given that the limit of equivalence
was 89% of the standard deviation of the differ-
ence between the two conditions. The safety
population included all randomized subjects who
took at least one dose of any study drug. The
evaluable population included all subjects in the
safety population who completed the study, with
no major protocol violations that would exclude
them from analysis, and for whom calculation
of the primary pharmacokinetic measures was
possible. Demographic and other baseline char-
acteristics of the study population were char-
acterized using the safety population and with
standard descriptive statistics.
For group 1 subjects, to address the primary
hypothesis of similarity of memantine AUC12
with and without DMQ, the individual natural
log-transformed memantine AUC12 values were
assessed in an analysis of variance (ANOVA)
model with factors for treatment (memantine with
DMQ or memantine alone) and subject. A 90%
CI for the natural log scale mean AUC12 differ-
ence (memantine after 8 days of DMQ – mem-
antine alone) was calculated. The limits of the
90% CI were exponentiated to obtain a 90% CI
for the memantine AUC12 true geometric
mean ratio (memantine after 8 days of DMQ/
memantine alone). A CI of within 0.8 and 1.25
would support the primary hypothesis. Tests of
significance were not appropriate because small,
consistent systemic exposure differences can be
statistically significant (p < 0.05) but not clinically
relevant. A similar procedure was used for Cmax,ss
and Cmin,ss. Summary statistics (minimum, max-
imum, median or harmonic mean) were com-
puted for the memantine tmax and apparent t½
values for each treatment (memantine with DMQ
or memantine alone). In addition, a plot of the
memantine pre-dose concentrations was exam-
ined to confirm whether steady state had been
attained by 31 days of memantine treatment.
Similar procedures were conducted in group 2
subjects to address the primary hypothesis for
this group of similarity of DMQ (separately for
dextromethorphan, dextrorphan and quinidine)
AUC12 with and without memantine. The in-
dividual log-transformed DMQ AUC12 values
were evaluated in an ANOVAmodel with factors
for treatment (DMQ with memantine and DMQ
alone) and subject, including only subjects in the
DMQ +memantine treatment group. A 90% CI
for the natural log scale mean AUC12 difference
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(DMQ after 31 days of memantine –DMQ alone)
was calculated. The same limits of the 90% CI as
in group 1 were used for the DMQ AUC12 true
geometric mean ratio (DMQ after 31 days
of memantine or DMQ alone) to assess whether
the primary group 2 hypothesis was supported.
Similar procedures as in group 1 were used
in group 2 to report and analyse Cmax,ss, Cmin,ss,
tmax and apparent t½, and to plot pre-dose
DMQ concentrations (dextromethorphan, dex-
trorphan and quinidine) to confirm whether
steady state was attained by 8 days of DMQ
administration.
With regard to safety and tolerability vari-
ables, AEs were reported and recorded through-
out the treatment and follow-up periods and were
coded using MedDRA Version 9.1; only treat-
ment-emergent AEs were included (i.e. those that
began or worsened after the start of treatment).
Laboratory tests, vital signs and ECG results were
summarized using descriptive statistics. Change
from baseline was summarized only for assess-
ments that had been made at similar time points
on different days.
The evaluable population was used for anal-
ysis of pharmacodynamic outcomes. For each
treatment group, pharmacodynamic values were
evaluated in an ANOVA model with factors for
treatment (DMQ +memantine or one drug alone)
and subject. A 90% CI was calculated for the
difference. No tests of significance were done.
Results
Subject Disposition and Baseline
Characteristics
A total of 52 subjects were randomized to
group 1 (n = 23) or group 2 (n = 29) [figure 2].
With the exception of one subject in group 2 who
withdrew consent before the study start, all ran-
domized subjects received at least one dose of
study treatment and were included in the safety






n = 23 (100%)
n = 17 (73.9%)
Total, n = 6 (26.1%)
Withdrawal of consent: n = 3 (13%)
AE or SAE: n = 1 (4.3%)
Positive alcohol breath




n = 28 (96.6%)
n = 17 (58.6%)
 Total, n = 12 (41.4%)1
Withdrawal of consent: n = 6 (20.7%)
AE or SAE: n = 3 (10.3%)






n = 34 (65.4%)
1 One subject randomized to group 2 withdrew consent before study start. 
Total
 withdrawals1
n = 18 (34.6%)
Safety set,
n = 51 (98.1%)
Fig. 2. Subject disposition. AE =adverse event; pop. = population; SAE = serious AE.
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was comprised of 34 (65.4%) subjects, 17 in each
group. A total of 18 (34.6%) randomized subjects
did not complete the trial, six (26.1%) in group 1
and 12 (41.4%) in group 2, including four (7.7%)
subjects who withdrew from the trial because of
an AE (one [4.3%] in group 1, and three [10.3%]
in group 2).
The randomized population was mostly male
(75%) with a mean age of 36.1 years and of varying
racial descent (table I). Age, body weight and BMI
did not differ markedly between the treatment
groups, although there were slight differences in sex
and race distribution (table I).Most subjects (n= 46
[90.2%]) were genotyped as CYP2D6 EMs, with
four subjects (7.8%) genotyped as a UM and one
subject (2.0%) as an IM (table I).
Pharmacokinetic Variables
Pharmacokinetic Parameters and Effects of
Concomitant Therapy
Examination of pre-dose concentration data
indicated that steady state was generally achieved
for all dose groups and treatments (table II). In
group 1, the mean, steady-state, pre-dose plasma
concentration of memantine given as mono-
therapy (day 32 [84.0 ng/mL]) was comparable to
the pre-dose memantine concentration (day 40
[77.7 ng/mL]) after 8 days of coadministration
with DMQ (table II). The 90%CIs of the ratios of
geometric means for AUC12 fell within the inter-
val of 0.8–1.25, indicating plasma concentrations
of memantine given alone compared with mem-
antine in combination with DMQ are similar
(figure 3). Mean steady-state AUC12 values of
memantine were also similar in group 1 on day 32
(memantinemonotherapy), group 1 on day 40 (after
the addition of DMQ) and group 2 on day 40 (after
the addition of memantine to DMQ monotherapy)
[table II]. In addition, the 90% CIs of the ratios of
geometric means for Cmax,ss (0.936) and Cmin,ss
(0.935) were also within the limits of 0.8–1.25.
In group 2, the mean pre-dose plasma con-
centration of dextromethorphan on day 8 of
DMQ monotherapy was 65.4 ng/mL, compared
with 76.7 ng/mL on day 40 with memantine co-
administration (table II). The 90% CIs for the
ratios of geometric means for AUC12 (figure 3)














Male 15 (65.2) 24 (82.8) 39 (75.0)
Female 8 (34.8) 5 (17.2) 13 (25.0)
Race, n (%)
White 7 (30.4) 12 (41.4) 19 (36.5)
Asian 4 (17.4) 6 (20.7) 10 (19.2)
Black or of African descent 5 (21.7) 4 (13.8) 9 (17.3)
Hispanic or Latino 5 (21.7) 6 (20.7) 11 (21.2)
Other 2 (8.7) 1 (3.4) 3 (5.8)
Weight, kg [mean (SD)] 76.9 (9.5) 76.1 (9.1) 76.5 (9.2)
BMI, kg/m2 [mean (SD)] 25.9 (2.6) 25.7 (2.3) 25.8 (2.4)
CYP2D6 predicted metabolizer phenotype, n (%)a
Extensive 19 (82.6) 27 (96.4) 46 (90.2)
Intermediate 1 (4.3) 0 (0.0) 1 (2.0)
Ultra-rapid 3 (13.0) 1 (3.6) 4 (7.8)
a n =28 in group 2 as one subject randomized to group 2 withdrew consent before the start of the study; predicted metabolizer phenotype at
baseline, based on each patient’s CYP2D6 genotype.
BMI = body mass index; CYP = cytochrome P450; SD = standard deviation.
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and Cmax,ss for day 40 fell entirely within the
limits of 0.8–1.25, indicating that dextromethor-
phan plasma concentrationswere similar before and
after the addition of memantine. Mean steady-state
AUC12 dextromethorphan values were also consis-
tent during DMQ monotherapy, and when DMQ
was added to memantine in group 1, and meman-
tine was added to DMQ in group 2 (table II).
For dextrorphan, the 90% CIs for the ratio of
geometric means of AUC12 (figure 3), Cmax,ss and
Cmin,ss for day 40 compared with day 8 all fell
within the 0.8–1.25 limits, indicating no differential
Table II. Steady-state pharmacokinetic assessments, evaluable populationa













Cmin,ss [arithmetic mean (SD)]
Memantine (ng/mL) 84.0 (26.8) 77.7 (30.3) 79.3 (24.1)
Dextromethorphan (ng/mL) 59.8 (28.0) 65.4 (18.4) 76.7 (22.0)
Dextrorphan (ng/mL) 63.1 (37.3) 66.7 (20.7) 77.4 (28.6)
Quinidine (ng/mL) 50.0 (40.0) 50.0 (40.0) 70.0 (40.0)
AUC12 [arithmetic mean (SD)]
Memantine (ng/mL) 1160.5 (360.2) 1111.6 (391.3) 1219.5 (282.6)
Dextromethorphan (ng/mL) 981.8 (374.7) 969.3 (248.7) 1060.9 (250.4)
Dextrorphan (ng/mL) 778.0 (437.1) 753.3 (213.8) 818.3 (215.6)
Quinidine (ng/mL) 1200.0 (500.0) 1000.0 (400.0) 1300.0 (500.0)
Cmax,ss [arithmetic mean (SD)]
Memantine (ng/mL) 106.4 (32.8) 102.7 (35.6) 106.4 (23.8)
Dextromethorphan (ng/mL) 94.9 (33.9) 98.6 (24.0) 108.8 (24.2)
Dextrorphan (ng/mL) 71.0 (36.3) 72.7 (21.6) 81.6 (27.5)
Quinidine (ng/mL) 200.0 (50.0) 200.0 (40.0) 200.0 (100.0)
Cmin,ss [arithmetic mean (SD)]
Memantine (ng/mL) 81.6 (26.0) 76.6 (30.0) 77.1 (22.7)
Dextromethorphan (ng/mL) 56.9 (25.4) 62.8 (18.5) 72.9 (19.4)
Dextrorphan (ng/mL) 51.2 (33.6) 57.1 (16.9) 60.8 (15.3)
Quinidine (ng/mL) 40.0 (30.0) 30.0 (30.0) 50.0 (40.0)
tmax (h) [median (range)]
Memantine 4.00 (0.0, 12.0) 4.00 (2.0, 6.0) 5.00 (3.0, 9.0)
Dextromethorphan 3.00 (3.0, 7.0) 3.00 (1.0, 6.0) 3.00 (2.0, 5.0)
Dextrorphan 3.00 (0.0, 13.0) 3.00 (0.0, 12.0) 1.00 (0.0, 12.0)
Quinidine 2.00 (2.0, 3.0) 2.00 (1.0, 3.0) 1.00 (1.0, 2.0)














Quinidine 7.3 (2.0) [7.6] 7.0 (2.1) [6.9] 6.7 (1.8) [6.3]
a Sample timings relative to administration of drug differ from group 1 to group 2; hence, direct comparison is not appropriate.
AUC12 =area under the plasma concentration-time curve from 0 to 12 hours; Cmax,ss =maximum steady-state concentration; Cmin,ss=
minimum steady-state concentration; DMQ =dextromethorphan 30mg/quinidine 30mg every 12 hours; SD = standard deviation; t½=
elimination half-life; tmax = time to reach maximum concentration.
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effect of memantine addition on dextrorphan
plasma concentrations, compared with DMQ
monotherapy. In addition,mean steady-stateAUC12
values of dextrorphan were similar during DMQ
monotherapy, when memantine was added to
DMQ andDMQwas added tomemantine mono-
therapy (table II). For quinidine, the 90% CIs for
the geometric means of AUC12 (figure 3), Cmax,ss
and Cmin,ss for day 40 compared with day 8 were
above the upper limit of 0.8–1.25, indicating that
the addition of memantine to DMQ increased
quinidine plasma concentrations. However, due
to the minimal quinidine plasma concentrations
produced by the low 30mg dose of quinidine in
the DMQ formulation, the absolute mean differ-
ences in quinidine plasma concentrations were small
(e.g. mean Cmax,ss was higher by approximately
0.03 mg/mL on day 40 than on day 8) [table II].
Safety and Tolerability
Overall, AEs occurred in 18 (78.3%) subjects
in group 1 and in 26 (92.9%) subjects in group 2.
No deaths or SAEs occurred during the study.
Memantine monotherapy was associated with a
lower incidence of subjects reporting AEs (9 of 20
[45.0%]) than with DMQ monotherapy (25 of 28
[89.3%]) [table III]. The incidence and severity
of AEs were also greater during DMQ mono-
therapy than during combination therapy in either
order of administration. In group 1, the addition
of DMQ to memantine monotherapy was asso-
ciated with a greater number of subjects reporting
at least one AE (14 of 19 subjects [73.7%]) than
during the previous memantine monotherapy at
the 10mg every 12 hours target dose (9 of 20
subjects [45.0%]) [table III]. However, in group 2,
fewer subjects reported at least one AE following
the addition of memantine to DMQ (14 of 20
subjects [70.0%]), compared with DMQ mono-
therapy (25 of 28 subjects [89.3%]) [table III].
The AE pattern in group 2 gave no indication
of a substantial drug interaction; indeed, the
total incidence and severity of AEs were actually
lower with combination therapy than with DMQ
monotherapy.
The most common AEs in group 1 following
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Fig. 3. Ratio of geometric mean area under the plasma concentration-time curve (AUC12) values at steady state of memantine, dextro-
methorphan (DM), dextrorphan (DX) and quinidine (Q) for memantine and dextromethorphan/quinidine (DMQ) given concomitantly versus
memantine or DMQmonotherapy. The geometric mean ratio is represented by themidline of each box; the 90% confidence intervals (CIs) for a
given ratio are indicated by values at the top and bottom of each box. The CIs of the geometric mean ratios were required to be within the
predefined interval of 0.8–1.25 (dotted boundary lines) for treatments to be considered pharmacokinetically similar; n= 17.
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pain, diarrhoea, flatulence, nausea, decreased ap-
petite, headache, dizziness, lethargy, somnolence,
restlessness, asthenia and elevated alanine amino-
transferase (ALT) [table III]. Clinically signifi-
cant increased ALT values ranged from 50 to
156U/L in group 1. In group 2, the most common
AEs following the addition of memantine toDMQ
were dizziness, headache, dry mouth and elevated
ALT values (table III). Clinically significant ALT
values in group 2 ranged from 59 to 193U/L. AEs
led to withdrawal of one subject in group 1, and
three subjects in group 2. The subject who with-
drew in group 1 had experienced nine central
nervous system (CNS) and gastrointestinal AEs
after 10 days of memantine monotherapy (i.e. 2
days after starting the 5mg every 12 hours dose);
these AEs included lightheadedness, dizziness,
insomnia, constipation, abdominal pain, nausea
and loose stools, as well as emotional lability.
Each of the three subjects who withdrew in group
2 also experienced multiple AEs, mostly involv-
ing CNS and gastrointestinal problems, which all
occurred from 1 to 3 days after the start of DMQ
monotherapy.
No abnormalities in physical examination or
vital signs were observed during the study. One
haematology and several clinical chemistry val-
ues were out of range to a potentially clinical
significant extent, mostly the hepatic enzymes
ALT and aspartate aminotransferase (AST). The
haematology result (elevated white blood cells)
occurred at follow-up in one female who was told
to consult with her family physician; the exact
date of resolution is unknown. Three subjects in
group 1 also had clinical chemistry values judged
to be clinically significant, all documented on day
41, including high ALT values in all three subjects
(50, 56 and up to 156U/L), and elevated AST in
one subject (72U/L); all values had returned to
normal at follow-up. Three subjects in group 2
also had clinical chemistry values judged to be
clinically significant. One subject, a 34-year-old

















Any AE [n (%)] 9 (45.0) 14 (73.7) 25 (89.3) 14 (70.0)
AE severity [n (%)]
Mild 4 (20.0) 7 (36.8) 14 (50.0) 11 (55.0)
Moderate 5 (25.0) 6 (31.6) 9 (32.1) 3 (15.0)
Severe 0 (0.0) 1 (5.3) 2 (7.1) 0 (0.0)
AE (MedDRA preferred term) incidence [n (%)]
Dizziness 0 (0.0) 8 (42.1) 8 (28.6) 4 (20.0)
Diarrhoea 0 (0.0) 7 (36.8) 6 (21.4) 1 (5.0)
Headache 4 (20.0) 5 (26.3) 5 (17.9) 3 (15.0)
Nausea 0 (0.0) 5 (26.3) 9 (32.1) 1 (5.0)
Somnolence 3 (13.0) 3 (15.8) 8 (28.6) 0 (0.0)
Alanine aminotransferase increased 0 (0.0) 3 (15.8) 0 (0.0) 2 (10.0)
Decreased appetite 1 (5.0) 2 (10.5) 8 (28.6) 0 (0.0)
Lethargy 0 (0.0) 2 (10.5) 0 (0.0) 0 (0.0)
Abdominal pain 0 (0.0) 2 (10.5) 1 (3.6) 0 (0.0)
Asthenia 0 (0.0) 2 (10.5) 3 (10.7) 0 (0.0)
Flatulence 0 (0.0) 2 (10.5) 0 (0.0) 1 (5.0)
Restlessness 0 (0.0) 2 (10.5) 0 (0.0) 0 (0.0)
Dry mouth 2 (10.0) 0 (0.0) 3 (10.7) 2 (10.0)
DMQ =dextromethorphan 30mg/quinidine 30mg every 12 hours; MedDRA =Medical Dictionary for Regulatory Activities.
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male, had high ALT (61U/L) and gamma gluta-
myl transpeptidase (GGT; 89U/L) on day 28,
which remained elevated at follow-up (ALT
101U/L; GGT 200U/L), but had returned to
normal, except for the GGT, at an unscheduled
visit 2 months and 11 days after first dosing. The
other two subjects in group 2 had elevated ALT
values (up to 61 and 193U/L) on day 41, one of
whom also had elevated AST (80U/L), which
had returned to normal at follow-up or at a later
unscheduled visit. No relationship was observed
between these chemistry value elevations and
plasma concentrations of the drugs for the treat-




Few differences in pharmacodynamic parameters
were observed among group 1 subjects on day 40
(DMQ +memantine) versus day 32 (memantine
monotherapy), or in group 2 subjects on day 40
(memantine+DMQ) versus day 8 (DMQ mono-
therapy). The pharmacodynamic test results gen-
erally showed either minimal to no effect or a
slight improvement with concomitant therapy,
compared with monotherapy (see Supplemental
Digital Content, http://links.adisonline.com/CDZ/
A5). The VAS for nausea showed no difference
during concomitant therapy versus monotherapy;
however, the VAS for dizziness showed a slight
increase in dizziness at 2 and 4 hours post-dose
with DMQ plus memantine therapy in group 1.
For the BDI-II, BAI and LSEQ, in both groups
the 90% CIs included 0, indicating no differences
in depression, anxiety or sleep scores, whenDMQ
was added to memantine or vice versa. Postural
stability was slightly improved in group 1 when
DMQ was added to memantine, but slightly de-
creased in several subtests (area of a 95% con-
fidence ellipsoid, eyes open and closed; average
velocity of the centre-of-pressure coordinates,
eyes open and closed) in group 2 when meman-
tine was added to DMQ, compared with the re-
spective monotherapies. Overall, no clinically
meaningful adverse pharmacodynamic effects of
the concomitant administration of DMQ and
memantine were observed.
Discussion
This open-label study showed minimal or no
drug interaction in healthy adult subjects result-
ing from coadministration of memantine and
DMQ. This general lack of drug interaction was
observed, regardless of the order in which the drugs
were added, and in terms of pharmacokinetic,
pharmacodynamic, and safety and tolerability
measures, including AEs, laboratory values, vital
signs and physical examination. The paucity of
pharmacodynamic and AE findings on dual ad-
ministration are especially noteworthy in light of
concerns that dual NMDA blockade with mem-
antine and DMQ could, theoretically, lead to in-
creased risk of AEs, particularly of the CNS.[20]
The primary study outcomes – 90% CIs of the
geometric mean ratios of monotherapy with
memantine and DMQ versus combination ther-
apy – were within the acceptance interval of
0.8–1.25, as was Cmax,ss, which would satisfy
general requirements for bioequivalence test-
ing.[33] The Cmin,ss of dextromethorphan was
slightly higher when memantine was added to
DMQ in group 2 subjects and the 90% CI of the
geometric mean ratio slightly exceeded the upper
limit of 1.25. In addition, slight increases in qui-
nidine plasma concentrations (AUC12, Cmin,ss
and Cmax,ss) were observed when memantine was
added to DMQ in group 2 subjects, compared
with DMQ monotherapy, which may be attrib-
utable to both quinidine and memantine under-
going renal secretion via similar renal cationic
transport.[20,22-24] However, as noted above, the
low dose of quinidine in the DMQ 30mg/30mg
formulation resulted in total quinidine plasma
concentrations that were near or below the LLQ
(0.05 mg/mL), making it impossible to extract a
log of zero; such data were given a value half of
the LLQ, rendering these calculations unreliable.
Moreover, the absolute mean difference in quini-
dine concentrations was small (about 0.03mg/mL),
and therefore any effect of memantine on quini-
dine concentrations in DMQ is unlikely to be
clinically relevant. With the exception of the
above, no pharmacokinetic differences associated
with concomitant memantine and DMQ com-
pared with their respective monotherapies were
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observed. In addition, the DMQ dose used in this
trial (dextromethorphan 30mg/quinidine 30mg)
was higher than the dose of the FDA-approved
DMQ formulation (dextromethorphan 20mg/
quinidine 10mg); therefore, any potential for inter-
action between DMQ andmemantine observed in
a study of this design would likely be greater than
any potential for interaction in clinical prac-
tice with concomitant use of these agents.
AEs were generally higher with DMQ mono-
therapy than with combination therapy. How-
ever, the overall incidence of AEs decreased with
duration of DMQ treatment, suggesting that
subjects were adjusting to the dose. As mentioned
above, it is worth noting that the DMQ dosage
used in this study was higher than the ultimately
approved dosage for treatment of PBA; in addi-
tion, DMQwas not titrated as is recommended in
the approved prescribing information document.
With regard to results for pharmacodynamic
measures, no interaction was found with coad-
ministration of DMQ and memantine on an array
of tests covering neurological, cognitive, gastro-
intestinal and psychological parameters. Un-
expectedly, performance on some subscales of the
tests appeared to be improved with concomitant
treatment, compared with either DMQ or mem-
antinemonotherapy.However, dizziness, as scored
by VAS, was increased with the addition of DMQ
to memantine in group 1 at 2 and 4 hours post-
dose. Several subtests of postural stability were
also slightly decreased with the addition of mem-
antine to DMQ in group 2; however, because
none of the other postural stability measures were
affected, this result did not appear to be clinically
meaningful.
A limitation of this study is that it was open
label; therefore, the pharmacodynamic results
should be interpreted with caution. In addition,
the study population was comprised of cogni-
tively intact, healthy volunteers rather than el-
derly patients with dementia and PBAwho would
be likely recipients of combined memantine and
DMQ therapy. Such older patients may also ex-
perience age-related changes in pharmacokinetic
and pharmacodynamic factors that could result
in unexpected drug effects. Nevertheless, the
pharmacokinetic and pharmacodynamic results
in this study in healthy volunteers suggest that
there may be no meaningful drug interaction be-
tween DMQ and memantine.
Conclusion
Twice-daily coadministration of memantine
10mg and dextromethorphan 30mg/quinidine
30mg does not result in a clinically meaningful
drug interaction, as reflected by the pharmaco-
kinetic, pharmacodynamic or tolerability mea-
sures, regardless of whether DMQ is added to
memantine at steady state or memantine is added
to DMQ at steady state, although a small (20–30%)
increase in quinidine concentrations is possible.
The results of this study suggest that memantine
and DMQ could be safely coadministered with-
out initial dose adjustment. However, as always
when combining two drugs with overlapping
pharmacology, patients should be monitored for
potential increase in AEs.
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